TECVAYLI

Manufacturer:

Janssen Biotech, Inc.

Name:

TECVAYLI

HCPCS Code Descriptor:

Injection, teclistamab-cqyv, 0.5 mg

Category:

J Code

HCPCS:

J9380

NDC(s):

57894-0450-01, 57894-0449-01

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Subcutaneous

About:

TECVAYLI is a Oncology drug manufactured by Janssen Biotech, Inc. and administered via the Subcutaneous route of administration. The J Code: J9380 is aligned to the drug TECVAYLI.

TECVAYLI is an antineoplastic that belongs to the class of drugs known as monoclonal antibodies. This medication works by attaching to the CD3 protein on T cells and the other the part of the drug attached to the B cell maturation antigen. This helps the T cells target and kill cancer cells. TECVAYLI can be used to treat specific cancers of the bone marrow. This medication is manufactured by Janssen Biotech and is aligned to the HCPCS code J9380. Patient assistance programs for TECVAYLI can be found through the Janssen Patient Assistance Program.